Efficacy of pantoprazole suspension for prevention of peptic ulcer.

A comparison of nasogastric pantoprazole suspension and intravenouse pantoprazole in prevention of peptic ulcer for critically ill patients with mechanical ventilation support: effects on 24-h intragastric pH.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015070220178N5

Enrollment

Registered

2015-08-12

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peptic ulcer prevention. Peptic ulcer, site unspecified

Interventions

Intervention 1: group A:pantoprazole, 40 mg intravenous once daily.The IV solution will be prepared by injecting 10 ml of 0.9% sodium chloride injection into the vial containing the lyophilized powd

Prevention

group A:pantoprazole, 40 mg intravenous once daily.The IV solution will be prepared by injecting 10 ml of 0.9% sodium chloride injection into the vial containing the lyophilized powder.This solution

group B: 25 cc of 2mg/ml simplified formulated pantoprazole suspension ( 50 mg pantoprazole) once daily nasogastrically and according to 75% bioavailability for suspension at last this dose equal

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria:Patients older than 18 years who are admitted to medical and surgical ICUs with support of mechanical ventilation at least for 48 hours and nasogastric tube . Exclusion criteria:active gastrointestinal bleeding,allergic history to pantoprazole ,co-administeration of prokinetic and other acid reducing drugs,past history of gastric surgery,nasogastric tube intolerance,liver failure,pregnancy, lactation,unexpected intragastric pH10.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Peptic ulcer prevention. Timepoint: basic ,first day,third day. Method of measurement: 24 hours intragastric PH monitoring.	—

Secondary

Measure	Time frame
Gastrointestinal bleeding rate after treatment intervention. Timepoint: 1,3 ,7,14 and 28 days after treatment intervention. Method of measurement: Data gathering sheet and nasogastric tube exam.;Drug adverse effect such as pneumonia rate. Timepoint: 3 ,7, 14 and 28 days after treatment intervention. Method of measurement: Sign and symptom gathering sheet and chest x-ray.;Frequency ofunderlying etiologic factore for mechanical ventilation support. Timepoint: at the begining of treatment. Method of measurement: Data gathering sheet.	—

Measure

Time frame

Gastrointestinal bleeding rate after treatment intervention. Timepoint: 1,3 ,7,14 and 28 days after treatment intervention. Method of measurement: Data gathering sheet and nasogastric tube exam.;Drug adverse effect such as pneumonia rate. Timepoint: 3 ,7, 14 and 28 days after treatment intervention. Method of measurement: Sign and symptom gathering sheet and chest x-ray.;Frequency ofunderlying etiologic factore for mechanical ventilation support. Timepoint: at the begining of treatment. Method of measurement: Data gathering sheet.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarjan Mokhtare

Colorectal Research Center, Rasoul Akram Hospital

mokhtare.m@iums.ac.ir-marjanmokhtare@yahoo.com-mokhtaredr@gmail.com+98 21 6655 4790

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026